"我们对本届进博会满怀期待，并始终以饱满热情与信心投身其中。 一方面，我们期待借助进博会 的聚势效应，与中国医疗健康事业同频共振。通过这一平台，我们可以更精准地捕捉本土医患的临床痛 点与未被满足的需求，加速引入更加符合中国诊疗场景的创新产品，让中国患者同步享受到全球领先的 医疗科技成果，为"健康中国 2030"贡献切实力量。另一方面，我们也期待以进博会为纽带，推动'中国 范式'的医疗创新走向世界。进博会的深层价值在于搭建起开放协作的桥梁，让本土创新力量与国际资 源更高效地对接。我们希望通过研发合作、商业推广等多元生态协作，推动更多贴合临床需求的创新方 案落地和服务本土患者，也助力'中国智造'优质成果走向更广阔的世界舞台，提升全球医疗健康领域的 协作效能。"波士顿科学表示。 资料显示，波士顿科学是全球领先的创新医疗科技公司，1979年成立于美国。46年来，波士顿科学 始终致力于为生命创新，每年研发投入占营收10%以上，目前共有10款产品或技术获得被誉为医药界诺 贝尔奖的"盖伦奖"或被提名，2016至2025年连续十年入选《财富》全球最受赞赏公司榜单。1997年，波 士顿科学正式进入中国市场，在华业务覆盖心脏、外 ...

Key Takeaways BSX posted Q2 adjusted EPS of 75 cents, up 20.9% and above guidance and consensus estimates. Q2 revenues rose 22.8% to $5.06B, driven by 26.8% Cardiovascular growth and strong U.S. performance. BSX raised 2025 sales growth forecast to 18-19% and EPS guidance to $2.95-$2.99 on solid portfolio momentum.Boston Scientific Corporation (BSX) posted second-quarter 2025 adjusted earnings per share (EPS) of 75 cents, up 20.9% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 4 ...

Core Insights - Boston Scientific (BSX) is expected to report its second-quarter 2025 results on July 23, with prior EPS of 75 cents exceeding estimates by 11.94% [1] - The company has consistently surpassed earnings estimates over the last four quarters, with an average surprise of 8.79% [1] Revenue and EPS Estimates - The Zacks Consensus Estimate for BSX's Q2 2025 revenues is $4.89 billion, reflecting an 18.7% increase year-over-year [2] - The EPS estimate for Q2 2025 is projected at 72 cents, indicating a 16.1% rise compared to the previous year [2] Performance Influencers - The MedSurg division is anticipated to maintain strong sales momentum, particularly in the Endoscopy business, driven by the Axios platform and technologies like OverStitch and Mantis clip [4] - The Urology business is expected to benefit from its core stone management franchise and the integration of the Axonics acquisition [5] - Neuromodulation growth is likely supported by the Brain and Pain franchises, with positive trends from Deep Brain Stimulation and the Intercept product [6] Segment Performance - MedSurg revenues are estimated at $1.68 billion, a 13.1% year-over-year increase [7] - The Cardiovascular unit is projected to perform well, with revenues expected to rise 8.3% year-over-year to $719.95 million [14] - Key contributors to Cardiovascular growth include the AGENT Drug-Coated Balloon and the completion of the SoniVie acquisition [10][11] Earnings Expectations - Boston Scientific has an Earnings ESP of +0.88%, indicating a higher likelihood of beating estimates [15] - The company holds a Zacks Rank of 2 (Buy), suggesting favorable conditions for earnings performance [16]